skip to Main Content

Arginine-Depleting Agent Added to Standard Therapy Shows Promise in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel (Abraxane) and gemcitabine has encouraging activity in patients with advanced pancreatic adenocarcinoma while demonstrating minimal additional toxicity over that with cytotoxic therapy alone.

In an open-label, single-arm phase Ib dose-escalation trial, 7 of 18 patients (39%) treated with various doses of ADI-PEG 20 combined with nab-paclitaxel and gemcitabine experienced partial response (PR) per RECIST v1.1 criteria, and 10 patients (56%) had stable disease (SD), according to data presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco.1 Seven patients experienced ≥3 toxicity that was considered to be potentially caused by ADI-PEG 20, including neutropenia in 4 patients. Read more . . .

Back To Top